cilia and flagella associated protein 53Genealiases: CCDC11 · HTX6
Q-omics provides the consensus-scored CFAP53 profile across patient tissues and cancer cell-line models. CFAP53 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CFAP53 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, CFAP53 RNA expression shows 18,927 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KICH, and THYM as cancer lineages where CFAP53 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFAP53 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFAP53 survival associations across molecular data types. CFAP53 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFAP53 RNA expression–survival associations across cancer types. High CFAP53 expression shows unfavorable associations in LGG and LIHC, but favorable associations in UVM, KIRP, BRCA and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for CFAP53 RNA expression.
This table summarizes CFAP53 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CFAP53. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFAP53 shows lower tumor expression in KICH, LUAD and THCA and higher tumor expression in BLCA, LIHC and HNSC. The KICH box plot shows higher CFAP53 RNA expression in normal versus tumor tissue (log2 FC = −2.135, t-test p < 0.001).
This table shows molecular features associated with CFAP53 in patient tissues and cancer cell lines. In patient samples, CFAP53 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CFAP53 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
